FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending May 2015
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--
 
 
 
 


GlaxoSmithKline plc

 Result of AGM

GlaxoSmithKline plc (‘GSK’) announces that at its Annual General Meeting (‘AGM’) today, all resolutions were passed by shareholders.

GSK AGM Poll Results

The following table shows the votes cast for each resolution:

Resolution
Total votes for*
%
Total votes against
%
Total votes cast
Votes withheld**
1
To receive the 2014 Annual Report
3,614,278,186
99.04
35,131,332
0.96
3,649,409,518
14,897,298
2
Approval of the Annual Remuneration Report
3,391,418,737
98.03
68,233,680
1.97
3,459,652,417
204,653,757
3
Election of Sir Philip Hampton
3,591,444,657
99.08
33,187,186
0.92
3,624,631,843
39,673,560
4
Election of Urs Rohner
3,646,088,522
99.85
5,657,074
0.15
3,651,745,596
12,559,808
5
Re-election of Sir Andrew Witty
3,636,239,584
99.57
15,745,701
0.43
3,651,985,285
12,323,435
6
Re-election of Professor Sir Roy Anderson
3,635,006,358
99.54
16,926,524
0.46
3,651,932,882
12,372,971
7
Re-election of Dr Stephanie Burns
3,640,064,153
99.67
11,957,663
0.33
3,652,021,816
12,284,037
8
Re-election of Stacey Cartwright
3,627,646,531
99.34
24,278,095
0.66
3,651,924,626
12,379,794
9
Re-election of Simon Dingemans
3,611,625,566
98.90
40,202,459
1.10
3,651,828,025
12,477,828
10
Re-election of Lynn Elsenhans
3,631,958,969
99.45
19,951,976
0.55
3,651,910,945
12,394,642
11
Re-election of Judy Lewent
3,616,440,612
99.03
35,558,235
0.97
3,651,998,847
12,307,006
12
Re-election of Sir Deryck Maughan
3,556,901,233
98.09
69,347,278
1.91
3,626,248,511
38,057,342
13
Re-election of Dr Daniel Podolsky
3,630,860,486
99.42
21,017,768
0.58
3,651,878,254
12,427,599
14
Re-election of Dr Moncef Slaoui
3,631,852,758
99.45
20,032,722
0.55
3,651,885,480
12,420,374
15
Re-election of Hans Wijers
3,558,527,772
99.02
35,109,224
0.98
3,593,636,996
70,668,857
16
Re-appointment of auditors
3,497,872,211
97.19
101,054,446
2.81
3,598,926,657
65,379,196
17
Remuneration of auditors
3,534,642,170
98.21
64,277,018
1.79
3,598,919,188
65,386,223
18
Authority for the company to make donations to political organisations and incur political expenditure
3,577,744,022
98.02
72,255,599
1.98
3,649,999,621
14,306,463
19
Authority to allot shares
3,546,475,883
97.19
102,584,391
2.81
3,649,060,274
15,248,087
20
Disapplication of pre-emption rights***
3,592,421,305
98.52
53,931,389
1.48
3,646,352,694
17,950,355
21
Authority for the company to purchase its own shares***
3,646,045,423
99.84
5,930,054
0.16
3,651,975,477
12,330,810
22
Exemption from statement of senior statutory auditor’s name
3,616,839,172
99.14
31,407,136
0.86
3,648,246,308
16,054,765
23
Authorise reduced notice of a general meeting other than an AGM***
3,235,833,877
88.66
413,929,365
11.34
3,649,763,242
14,542,185
24
Approval of GSK Share Value Plan
3,528,728,822
96.72
119,600,001
3.28
3,648,328,823
15,980,071


Notes:
*
Includes discretionary votes.
**
A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "For" or "Against" a resolution.
***
Indicates Special Resolutions requiring a 75% majority.

 
Sir Christopher Gent, Tom de Swaan and Jing Ulrich did not stand for re-election as Directors, and stepped down from the Board with effect from the conclusion of the AGM.
 
 
In accordance with section 430(2B) of the Companies Act 2006, GSK confirms that Sir Christopher Gent, Tom de Swaan and Jing Ulrich will receive payment of fees for service whilst a Director but no other remuneration payment or payment for loss of office will be made in connection with their departure.
 
The following table provides further relevant information:

 
GSK's
Fifteenth AGM
(2015)
GSK's
Fourteenth AGM
(2014)
Issued share capital (excluding Treasury Shares)
4,866,216,110
4,861,007,167
Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares)
75.30%
74.05%
Total shareholder population
137,658
140,792
Total number of proxies lodged
8,686
8,333
% of shareholders who lodged proxies
6.31%
5.92%
Number of shareholders, corporate representatives and proxies who attended the AGM
403
429


V A Whyte
Company Secretary

7 May 2015

These results will shortly be available on the company's website at www.gsk.com.
 
GSK enquiries:
 
      
GSK enquiries:
      
UK Media enquiries:
David Mawdsley
+44 (0) 20 8047 5502
(London)
 
Simon Steel
+44 (0) 20 8047 5502
(London)
 
Sarah Spencer
+44 (0) 20 8047 5502
(London)
       
US Media enquiries:
Stephen Rea
+1 215 751 4394
(Philadelphia)
 
Sarah Alspach
+1 202 715 1048
(Washington, DC)
 
Mary Anne Rhyne
+1 919 483 0492
(North Carolina)
       
Analyst/Investor enquiries:
Ziba Shamsi
+44 (0) 20 8047 5543
(London)
 
Tom Curry
+ 1 215 751 5419
(Philadelphia)
 
Gary Davies
+44 (0) 20 8047 5503
(London)
 
James Dodwell
+44 (0) 20 8047 2406
(London)
 
Jeff McLaughlin
+1 215 751 7002
(Philadelphia)
       
       
       
       
       




 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: May 7, 2015 
 
 
By: VICTORIA WHYTE
----------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc